GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Debt-to-Revenue

Qiagen NV (Qiagen NV) Debt-to-Revenue : 0.75 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Qiagen NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $610 Mil. Qiagen NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $922 Mil. Qiagen NV's annualized Revenue for the quarter that ended in Dec. 2023 was $2,037 Mil. Qiagen NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.75.


Qiagen NV Debt-to-Revenue Historical Data

The historical data trend for Qiagen NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Debt-to-Revenue Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 1.04 0.87 0.88 0.78

Qiagen NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.97 0.95 0.78 0.75

Competitive Comparison of Qiagen NV's Debt-to-Revenue

For the Diagnostics & Research subindustry, Qiagen NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Debt-to-Revenue falls into.



Qiagen NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Qiagen NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(610.238 + 921.824) / 1965.311
=0.78

Qiagen NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(610.238 + 921.824) / 2036.648
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Qiagen NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (Qiagen NV) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Executives
Prof. Dr. Elaine R. Mardis Supervisory Board
Roland Sackers Board of Directors
Thierry Bernard Board of Directors
Lawrence A. Rosen Supervisory Board